Community-based evaluation of etanercept in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 4, 2006, Pages 665-670

  Farahani, Pendar ^a   Levine, Mitchell ^a,b   Gaebel, Kathryn ^a   Wang, Edward C Y ^c   Khalidi, Nader ^b  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Cephalon Inc   (United States)

Author keywords

Cohort study; Etanercept; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; CODEINE; CORTISONE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CANADA; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG UTILIZATION; EVALUATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH CARE UTILIZATION; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; WORK DISABILITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COMMUNITY HEALTH SERVICES; DRUG EVALUATION; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33645824970     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
2. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
3. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;6:1443-50.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Yazici Y, Erkan D, Kulman I, Belostocki K, Harrison MJ. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world". Ann Rheum Dis 2002;61:638-40.
6. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
7. Kremer JM, Weinblatt ME, Bankhurst AD, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis - Continued observations. Arthritis Rheum 2003;48:1493-9.
8. Moreland LM, Cohen SB, Baumgartner SW, et al. Long-term use of Enbrel (R) in patients with DMARD-refractory rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl:S270.
9. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
10. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
11. Ware J. SF-36 Health Survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Centre; 1993.
12. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
13. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999;42:2220-30.
14. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
15. Registry of etanercept (Enbrel®) in children with juvenile rheumatoid arthritis. wwwclinicaltrials gov/ct/gui/show/NCT00078793 2005.
16. The British Society for Rheumatology Biologies Register. [Internet.] Available from: http://www.arc.man.ac.uk/webbiologicsreg.htm. Accessed December 11, 2005.
17. van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003;5:R347-R351.